BEIJING–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, announced preliminary results of the Phase II KUNPENG study of Vebreltinib in Patients (Pts) with advanced Non-small cell lung cancer (NSCLC) Harboring MET (mesenchymal-epithelial transition factor) alterations (Poster# 1379P) at the European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
